Cutaneous Eruptions and Lifileucel/Interleukin 2 in Individuals With Metastatic Melanoma - PubMed
4 hours ago
- #melanoma
- #cutaneous-eruptions
- #lifileucel
- Lifileucel is an autologous tumor-infiltrating lymphocyte (TIL) therapy for advanced/metastatic melanoma resistant to anti-PD-1 and/or BRAF inhibitors.
- In the C-144-01 phase 2 trial, cutaneous eruptions occurred in 37.2% of patients, with 50% experiencing them in a retrospective cohort of 44 individuals after a median of 4 days post-TIL.
- The eruptions were often purpuric morbilliform and centrally predominant based on photographic evidence from 63.6% of affected patients.
- Cutaneous eruptions were associated with favorable short-term tumor response at 42 days, showing statistically significant odds ratios across multiple analyses, but not at 90 days.
- Objective response rates did not significantly differ between high (4-6 doses) and low (1-3 doses) IL-2 groups, indicating eruptions may serve as an early efficacy marker during hospitalization.